Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) rose 3.1% on Monday . The company traded as high as $5.52 and last traded at $5.37, with a volume of 590,002 shares trading hands. The stock had previously closed at $5.21.

A number of research analysts have recently issued reports on the company. Guggenheim reissued a “buy” rating and issued a $12.00 target price on shares of Aralez Pharmaceuticals in a report on Monday, August 15th. Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Aralez Pharmaceuticals in a report on Sunday, August 14th.

The stock’s 50-day moving average price is $4.03 and its 200-day moving average price is $4.21. The company’s market cap is $364.76 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The business earned $12.60 million during the quarter, compared to analysts’ expectations of $9.70 million. The firm’s revenue for the quarter was up 142.3% on a year-over-year basis. On average, equities research analysts forecast that Aralez Pharmaceuticals Inc. will post ($0.98) EPS for the current year.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.